EJC Supplements
Volume 9, Issue 2 , Pages 11-15 , October 2011

Anthracyclines in the management of metastatic breast cancer: state of the art

  • Alessandra Gennari

      Affiliations

    • Corresponding Author InformationCorresponding author. Alessandra Gennari, Division of Medical Oncology, Galliera Hospital, Mura delie Cappuccine 15, 16125 Genoa, Italy. Tel.: +39010 5634502; fax: +39 010 5634507
    • ,
  • Mauro D'Amico

References 

  1. Fossati R , Confalonieri C , Torri V , et al.   Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women . J Clin Oncol . 1998;6:3439–3460
  2. Lord S , Ghersi D , Gattellari M , Wortley S , Wilcken N , Simes J . Antitumour antibiotic containing regimens for metastatic breast cancer . Cochrane Database Syst Rev . 2004;4: CD003367.
  3. Piccart-Gebhart MJ , Burzykowski T , Buyse M , et al.   Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer . J Clin Oncol . 2008;26:1980–1986
  4. Gennari A , Conte P , Rosso R , Orlandini C , Bruzzi P . Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies . Cancer . 2005;104:1742–1750
  5. Chia SK , Speers CH , D'Yachkova Y , et al.   The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer . Cancer . 2007;110:973–979
  6. National Comprehensive Cancer Network. Practice guidelines in oncology, v.2.2010. Breast cancer . Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed 24 September 2010.
  7. Cardoso F , Senkus-Konefka E , Fallowfield L , et al.   Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up . Ann Oncol . 2010;21(Suppl 5):v15–v19
  8. Cardoso F , Bedard PL , Winer EP , et al. , on behalf of the ESO-MBC Task Force    International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy . J Natl Cancer Inst . 2009;101:1174–1181
  9. Carrick S , Parker S , Wilcken N , et al.   Single agent versus combination chemotherapy for metastatic breast cancer . Cochrane Database Syst Rev . 2005;2: CD003372.
  10. Sledge GW , Neuberg D , Bernardo P , et al.   Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) . J Clin Oncol . 2003;21:588–592
  11. O'Shaughnessy J , Miles D , Vukelja S , et al.   Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results . J Clin Oncol . 2002;20:2812–2823
  12. Stockler M , Wilcken N , Coates A . Chemotherapy for metastatic breast cancer - when is enough enough? . Eur J Cancer . 1997;33:2147–2148
  13. Muss HB , Case LD , Richards F , et al.   Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association . N Engl J Med . 1991;325:1342–1348
  14. Falkson G , Gelman R , Pandya K , et al.   Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment . J Clin Oncol . 1998;16:1669–1676
  15. Coates A , Gebski V , Bishop JF , et al.   Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies . N Engl J Med . 1987;317:1490–1495
  16. Harris AL , Cantwell BM , Carmichael J , et al.   Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer . Lancet . 1990;335:186–190
  17. Ejlertsen B , Pfeiffer P , Pedersen D , et al.   Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months . Eur J Cancer . 1993;29A:527–531
  18. Gregory RK , Powles TJ , Chang JC , Ashley S . A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast . Eur J Cancer . 1997;33:2194–2197
  19. French Epirubicin Study Group  . Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment . J Clin Oncol . 2000;18:3115–3124
  20. Nooij MA , de Haes JC , Beex LV , et al.   Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: clinical outcomes and oncologists' preferences . Eur J Cancer . 2003;39:614–621
  21. Gennari A , Amadori D , De Lena M , et al.   Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer . J Clin Oncol . 2006;24:3912–3918
  22. Mayordomo JI , Baena JM , Cirera L , et al.   Final results of a randomized trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer . J Clin Oncol . 2009;27(Suppl 15S):1001
  23. Alba E , Ruiz-Borrego M , Margelí M , et al.   Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study . Breast Cancer Res Treat . 2010;122:169–176
  24. Greenberg PA , Hortobagyi GN , Smith TL , Ziegler LD , Frye DK , Buzdar AU . Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer . J Clin Oncol . 1996;14:2197–2205
  25. Morabito A , Piccirillo MC , Monaco K , et al.   First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment . Oncologist . 2007;12:1288–1298
  26. Kardinal CG , Perry MC , Korzun AH , Rice MA , Ginsberg S , Wood WC . Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081 . Cancer . 1988;61:415–419
  27. Venturini M , Bruzzi P , Del Mastro L , et al.   Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer . J Clin Oncol . 1996;14:764–773
  28. Pierga JY , Robain M , Jouve M , et al.   Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients . Ann Oncol . 2001;12:231–237
  29. Gennari A , Bruzzi P , Orlandini C , et al.   Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy . Br J Cancer . 2004;90:962–967
  30. Batist G , Harris L , Azarnia N , Lee LW , Daza-Ramirez P . Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis . Anticancer Drugs . 2006;17:587–595
  31. Batist G , Ramakrishnan G , Rao CS , et al.   Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer . J Clin Oncol . 2001;19:1444–1454
  32. Harris L , Batist G , Belt R , et al.   Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma . Cancer . 2002;94:25–36
  33. Slamon DJ , Leyland-Jones B , Shak S , et al.   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 . N Engl J Med . 2001;344:783–792
  34. Gennari A , De Tursi M , Carella C , et al.   Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer . Breast Cancer Res Treat . 2009;115:131–136
  35. Theodoulou M , Batist G , Campos S , Winer E , Welles L , Hudis C . Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer . Clin Breast Cancer . 2009;9:101–107
  36. Venturini M , Bighin C , Puglisi F , et al.   A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer . Breast . 2010;19:333–338
  37. Livi L , Meattini I , De Luca Cardillo C , et al.   Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis . Tumori . 2009;95:422–426
  38. Leonard RC , Williams S , Tulpule A , Levine AM , Oliveros S . Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet) . Breast . 2009;18:218–224

PII: S1359-6349(11)70004-0

doi: 10.1016/S1359-6349(11)70004-0

EJC Supplements
Volume 9, Issue 2 , Pages 11-15 , October 2011

Article Tools